European Association for the Study of the Liver 2017: Update From Amsterdam

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide continuing medical education (CME) effort for physicians on the evolving challenges of managing HCV infection. This webinar highlights key data presented at EASL 2017, the International Liver Congress in Amsterdam, Netherlands, held from April 19 to April 23. The most up-to-date information on investigational direct-acting antiviral agents, current recommendations for managing hepatitis C virus (HCV) infection, and other important information that may impact your clinical practice are discussed.

Learning Objectives

At the conclusion of this webinar, participants will be able to:

• Describe recent data from important studies in hepatology, infectious diseases, and pharmacology
• List investigational direct-acting antiviral agents currently in development
• Describe current approaches to the management of hepatitis C virus (HCV) infection in HIV/HCV coinfection

Registration

Who Should Attend

This webinar is designed for physicians who have a good understanding of the basics of HCV transmission, testing, and management, and have managed HCV infection in at least 5 patients.

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Wednesday, May 3, 2017, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.